Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]F-siPSMA-14
- Development stage
- Unknown
- Lead developer
- Technical University of Munich
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
`[18F]F-siPSMA-14` (also referred to as `[18F]siPSMA-14`) is a novel silicon-based radiofluorinated prostate-specific membrane antigen (PSMA)-targeted radioligand developed for positron emission tomography (PET) imaging of prostate cancer. It incorporates a silicon-fluoride acceptor (SiFA) moiety, which enables simple, rapid, and scalable radiolabeling via a one-step room-temperature fluorine-18 for fluorine-19 isotopic exchange reaction, avoiding the need for complex high-temperature synthesis or HPLC purification. Preclinically, `[18F]F-siPSMA-14` has demonstrated high binding affinity and specific accumulation in PSMA-positive tumor models. In clinical proof-of-concept studies, it has shown favorable biodistribution, moderate radiation dosimetry, and intense uptake in primary and metastatic prostate cancer lesions, enabling high-contrast PET imaging even without forced diuresis.
- Other names
- siPSMA-14siPSMA14siPSMA 14siPSMA-14 (TFA salt)
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on [18F]F-siPSMA-14.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]F-siPSMA-14.